BioPartnering North America

BioPartnering North America

November 07, 2006 16:40 ET

BioPartnering North America, BPN, Calls for Applications to Present

Unique Opportunity for International Biotech Companies to Showcase Their Technology and Products

VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - Nov. 7, 2006) - Technology Vision Group LLC (TVG) is pleased to announce that it is accepting applications to present at the 5th Annual BioPartnering North America (BPN), which will be held in Vancouver, B.C., Canada, on February 4-6, 2007, and co-hosted again this year by BC Biotech, BioAlberta and BIOTECanada.

Applications to present can be submitted online at: www.techvision.com/bpn/registration/presenter/apply.php.

BioPartnering North America provides unparalleled opportunities for innovative biotech companies from across the world to showcase their technologies and products and form valuable and meaningful business relationships. BPN 2006 was very successful and featured 76 company presentations and over 900 delegates from nearly 500 international biotech, pharma and financial companies.

BPN 2007 will again feature all the program highlights that have contributed to its overwhelming success with Open House presentations, Emerging Company presentations, BioPartnering Leadership sessions, sponsor workshops and several networking opportunities built into everyday of the conference.

Emerging Company presentations

This year BPN will showcase twenty young companies from North America, Europe and Asia in 14-minute podium presentations in the main plenary hall. Each company will then be available for private discussions directly afterwards. In the past BPN has featured many young companies that have gone on to become the industry's most important players.

"In our experience BioPartnering North America and BioPartnering Europe have proven to be the two most time-efficient and cost-effective events for making contact with prospective partners. Importantly, major pharma and biotech companies always appear to be well represented. It is also worth noting that, in Vancouver and London, Technology Vision Group LLC has chosen two superb venues for the events - providing lots of opportunity for informal interactions amongst companies," stated Thor Borgford, President & CEO of Twinstrand Therapeutics Inc. of British Columbia, Canada.

Open House presentations

A trademark of BPN is the Open House presentations featuring 56 biopharmaceutical and diagnostics companies, each giving interactive presentations in specially constructed booths. Presenters are available during a two-hour period for informal discussions with business development executives, and devise unique ways to showcase aspects of their business. A great benefit of the Open House is that delegates are able to ask the presenters detailed questions and sessions are lively and interactive.

"Incredible planning, awesome event coordination, and tremendous turn-out, BioPartnering North America sets the standard for how these events should be run," stated Eric Adams, President and CEO of enGene Inc., a Vancouver-based biotechnology company. "The efficiency of the program combined with high attendance from pharma and biotech make this the leading event on my partnering schedule each year."

biopartnering.com & video profiles foster B2B opportunities

BPE delegates will once again be able to search partnering opportunities through keyword searches of detailed profiles on all companies, contact other delegates, arrange private meetings, and reserve meeting rooms in advance of the conference. In addition, biopartnering.com now offers a unique component - video profiles. This exciting new feature will give Open House and Emerging Company presenters the ability to add a short video to their biopartnering.com profile and thus promote their company in a dynamic and engaging manner.

Full details about BioPartnering North America online at: http://www.techvision.com/bpn

Conference Sponsors

Angiotech Pharmaceuticals, Inc., AstraZeneca, PricewaterhouseCoopers, Cooley Godward Kronish LLP, Farris, Vaughan, Wills & Murphy LLP, Ferghana Partners Group, Morrison & Foerster, Pfizer, Bristol-Myers Squibb Company, Merck & Co., Inc., Ministry of Advanced Education, NovaQuest, Novartis, QLT Inc., Seed Intellectual Property Law Group PLLC, UK Trade & Investment, anapharm, Genome British Columbia, Life Science Analytics, Marsh Canada Limited , UBC University - Industry Liaison Office

Conference Supporters

Bio Business, BioExecutive International, Biotechnology Focus, BioWorld Today, CCNMatthews , Citigate Dewe Rogerson, Contact Canada®, U.S. Commercial Service, Global Bioscience Partnership

2006 Emerging Company Presenters

4 AZA Bioscience, Acologix, Inc., Adnavance Technologies, Inc., AerovectRx Corporation, Alder Biopharmaceuticals, Antibe Therapeutics Inc.,AquaGenvx Pharmaceuticals, Cardiome Pharma Corp., EcoBiotics, Evolva AG, iCo Therapeutics Inc., KAI Pharmaceuticals, Nerites Corporation, Nura Inc., PainCeptor Pharma, Predix Pharmaceuticals, Reata Pharmaceuticals, Inc., Replikun Biotech Pty Limited, Talisker Pharma Ltd., and Vitae Pharmaceuticals, Inc.

2006 Open House Presenters

Alchemia Limited, Allon Therapeutics, Inc., Alphora Research Inc., Antisoma, Atugen AG, Avidex Ltd., Biolex Theraputics, BioWa, Inc., Boston Life Sciences, Inc., CANTEST BioPharma Services, Celator Pharmaceuticals, Cell Signals Inc., Corgentech, Curis, Inc., Engene Inc., Evolutec Group Plc, Forbes Medi-Tech Inc., ImaRx Therapeutics, Inc., Ingenium Pharmaceuticals, Inimex Pharmaceuticals, Inc., InNexus Biotech, Jiangsu Simcere Pharmaceutical R&D Co., Ltd., Liponex Inc., MaxCyte, Inc., Medicago Inc., Meristem Therapeutics, Miltenyi Bioprocess, Novacta Biosystems Ltd., NovaDel Pharma, Novozymes A/S, Nycomed, Oncolytics Biotech Inc., Oxford BioMedica, Paradigm Therapeutics Ltd., Patheon Inc., Pharmacyclics, Product Safety Labs, Protox Therapeutics, PTC Therapeutics, Inc., QSV Biologics Limited, Santaris Pharma, SemBioSys Genetics, Stem Cell Therapeutics Corp., TopoTarget UK Ltd., Torcan Chemical Ltd., ToxTest, Transition Therapeutics Inc., Trigen Holdings AG, Trophos, Urigen, Xantos Biomedicine AG, XOMA Ltd., and YM BioSciences Inc.

Contact Information